Evidence map›Paper›PMID 39084266›Full record

ArticleToxicology and applied pharmacology2024

A preclinical model of severe NASH-like liver injury by chronic administration of a high-fat and high-sucrose diet in mice.

Rose A Willett, Volodymyr P Tryndyak, Jennifer M Hughes Hanks, Lana Elkins, Suresh K Nagumalli, Mark I Avigan, Sharon A Ross, Gonçalo Gamboa da Costa, Frederick A Beland, Ivan Rusyn and 1 more

Abstract read
In one paragraph

Article in Toxicology and applied pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Mediation analysis of the molecular phenotypes in a severe MASH-like liver injury mouse model.Toxicological sciences : an official journal of the Society of Toxicology · 2025
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Rose A WillettDivision of Biochemical Toxicology, FDA-National Center for Toxicological Research, Jefferson, AR, USA.
Volodymyr P TryndyakDivision of Biochemical Toxicology, FDA-National Center for Toxicological Research, Jefferson, AR, USA.
Jennifer M Hughes HanksToxicologic Pathology Associates, Jefferson, AR, USA.
Lana ElkinsToxicologic Pathology Associates, Jefferson, AR, USA.
Suresh K NagumalliDivision of Biochemical Toxicology, FDA-National Center for Toxicological Research, Jefferson, AR, USA.
Mark I AviganOffice of Pharmacovigilance and Epidemiology, FDA-Center for Drug Evaluation and Research, Silver Spring, MD, USA.
Sharon A RossDivision of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA.
Gonçalo Gamboa da CostaOffice of the Director, FDA-National Center for Toxicological Research, Jefferson, AR, USA.
Frederick A BelandDivision of Biochemical Toxicology, FDA-National Center for Toxicological Research, Jefferson, AR, USA.
Ivan RusynDepartment of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, TX, USA.
Igor P PogribnyDivision of Biochemical Toxicology, FDA-National Center for Toxicological Research, Jefferson, AR, USA. Electronic address: igor.pogribny@fda.hhs.gov.

Funding

Chromatin regions, genes and pathways that confer susceptibility to chemical-induced DNA damageR01ES029911 · NIEHS · TEXAS A&M AGRILIFE RESEARCH · PI RUSYN, IVAN, THREADGILL, DAVID W. · 2019 to 2023
$3.3M
NIEHS NIH HHS R01 ES029911
6 · The paper itself

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a progressive liver disease, affecting 38% of adults globally. If left untreated, NAFLD may progress to more advanced forms of the disease, including non-alcoholic steatohepatitis (NASH), liver cirrhosis, and fibrosis. Early NAFLD detection is critical to prevent disease progression. Using an obesogenic high-fat and high-sucrose (HF/HS) diet, we characterized the progression of NAFLD in male and female Collaborative Cross CC042 mice after 20-, 40-, and 60-week intervals of chronic HF/HS diet feeding. The incidence and severity of liver steatosis, inflammation, and fibrosis increased in both sexes over time, with male mice progressing to a NASH-like disease state faster than female mice, as indicated by earlier and more pronounced changes in liver steatosis. Histopathological indication of macrovesicular steatosis and gene expression changes of key lipid metabolism genes were found to be elevated in both sexes after 20 weeks of HF/HS diet. Measurement of circulating markers of inflammation (CXCL10 and TNF-α), histopathological analysis of immune cell infiltrates, and gene expression changes in inflammation-related genes indicated significant liver inflammation after 40 and 60 weeks of HF/HS diet exposure in both sexes. Liver fibrosis, as assessed by Picosirius red and Masson's trichrome staining and changes in expression of key fibrosis related genes indicated significant changes after 40 and 60 weeks of HF/HS diet exposure. In conclusion, we present a preclinical animal model of dietary NAFLD progression, which recapitulates human pathophysiological and pathomorphological changes, that could be used to better understand the progression of NAFLD and support development of new therapeutics.

Indexed as

Diet, High-FatDisease Models, AnimalLiverNon-alcoholic Fatty Liver DiseaseAnimalsDietary SucroseDisease ProgressionFemaleLipid MetabolismLiver CirrhosisMaleMiceDietary SucroseCollaborative crossNon-alcoholic fatty liver disease (NAFLD)Non-alcoholic steatohepatitis (NASH)Obesogenic dietPreclinical mouse model

Identifiers

PMID39084266
PMCPMC11711102

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.